These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20030468)

  • 1. Decreased T-cell responses to influenza vaccination in patients with heart failure.
    Vardeny O; Moran JJ; Sweitzer NK; Johnson MR; Hayney MS
    Pharmacotherapy; 2010 Jan; 30(1):10-6. PubMed ID: 20030468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 5. Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study.
    Van Ermen A; Hermanson MP; Moran JM; Sweitzer NK; Johnson MR; Vardeny O
    Eur J Heart Fail; 2013 May; 15(5):560-4. PubMed ID: 23291729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of persistence of influenza vaccine antibody titers in patients with heart failure.
    Albrecht CM; Sweitzer NK; Johnson MR; Vardeny O
    J Card Fail; 2014 Feb; 20(2):105-9. PubMed ID: 24361852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease.
    Hagihara Y; Ohfuji S; Watanabe K; Yamagami H; Fukushima W; Maeda K; Kamata N; Sogawa M; Shiba M; Tanigawa T; Tominaga K; Watanabe T; Fujiwara Y; Hirota Y; Arakawa T
    J Crohns Colitis; 2014 Mar; 8(3):223-33. PubMed ID: 24011513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings.
    Madan RP; Tan M; Fernandez-Sesma A; Moran TM; Emre S; Campbell A; Herold BC
    Clin Infect Dis; 2008 Mar; 46(5):712-8. PubMed ID: 18230041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the trivalent influenza vaccination in Thai patients with hemodialysis or kidney transplant compared with healthy volunteers.
    Krairittichai U; Chittaganpitch M
    J Med Assoc Thai; 2013 Mar; 96 Suppl 3():S1-7. PubMed ID: 23682516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung transplant patients' T cell responses to influenza vaccine viruses between seasons.
    Hayney MS; Moran J; Wiegert NA; Burlingham WJ
    Vaccine; 2008 May; 26(21):2596-600. PubMed ID: 18420314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell responses are better correlates of vaccine protection in the elderly.
    McElhaney JE; Xie D; Hager WD; Barry MB; Wang Y; Kleppinger A; Ewen C; Kane KP; Bleackley RC
    J Immunol; 2006 May; 176(10):6333-9. PubMed ID: 16670345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Influenza Vaccination History on Changes in Hemagglutination Inhibition Titers After Receipt of the 2015-2016 Influenza Vaccine in Older Adults in Hong Kong.
    Ng TWY; Perera RAPM; Fang VJ; Yau EM; Peiris JSM; Tam YH; Cowling BJ
    J Infect Dis; 2020 Jan; 221(1):33-41. PubMed ID: 31282541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
    Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
    Kositanont U; Assantachai P; Wasi C; Puthavathana P; Praditsuwan R
    Viral Immunol; 2012 Dec; 25(6):471-6. PubMed ID: 23061793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination against influenza in patients with systemic sclerosis.
    Litinsky I; Balbir A; Zisman D; Mandelboim M; Mendelson E; Feld J; Braun Y; Anouk M; Kaufman I; Paran D; Caspi D; Elkayam O
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S7-11. PubMed ID: 22409886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
    Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults.
    Loebermann M; Fritzsche C; Geerdes-Fenge H; Heijnen E; Kirby D; Reisinger EC
    Infection; 2019 Feb; 47(1):105-109. PubMed ID: 30298473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months.
    Lee JH; Cho HK; Kim KH; Lee J; Kim YJ; Eun BW; Kim NH; Kim DH; Jo DS; Kim HM; Kim YK
    J Korean Med Sci; 2019 Dec; 34(46):e279. PubMed ID: 31779056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.